The first COPD patient has been dosed in a Phase 1b COPD trial testing Bambusa Therapeutics’ dual-target therapy BBT002.

Metastatic melanoma is the most aggressive form of skin cancer. In an effort to achieve targeted therapy for metastatic melanoma, researchers recently developed a new radioactive drug that emits alpha ...

Cancer therapy and synthetic biology are converging around a shared problem that has long frustrated oncologists and ...

More effective combinations of targeted therapies, strategies to minimize side effects, the use of subcutaneous rather than intravenous immunotherapies, and artificial intelligence (AI) tools to ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

Researchers discover new insights into how dual-target drug may supercharge cancer-fighting immune cells. Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), in ...

A computational approach by St. Jude Children's Research Hospital scientists promises to make designing T cell-based immunotherapies that target two cancer-related antigens at the same time far easier ...

Researchers first recognized antimony-119 (Sb-119) more than two decades ago as a potentially promising radioactive isotope ...